STRO vs TOST · rev $62.0M vs P/E 161, rev $4.96B
Sutro Biopharma (STRO) versus Toast Inc (TOST) — a side-by-side from cached financials, not a winner call.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Toast Inc (TOST) is a software - infrastructure company listed on US.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
Latest reported TOST revenue for 2024-12-31 was $4.96B. Net income was $19.0M. Revenue was up 28.3% from 2023-12-31 to 2024-12-31. TOST currently screens at market cap $25.21B and trailing P/E 161.4.
STRO currently screens at market cap $470.8M. TOST currently screens at market cap $25.21B and trailing P/E 161.4.
Not investment advice. Open the STRO and TOST stock pages for the full models.
Not investment advice.